Loading clinical trials...
Loading clinical trials...
Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease by FAPI PET/CT and 5.0T-MRI
Conditions
Interventions
[18F]AlF-NOTA-FAPI-04PET/CT
5.0-T high-resolution MRI
Locations
1
China
Peking University Third Hospital
Beijing, China
Start Date
November 11, 2025
Primary Completion Date
December 31, 2026
Completion Date
May 31, 2027
Last Updated
February 20, 2026
NCT06112340
NCT06359795
NCT05012033
NCT06557850
NCT07155668
NCT06625411
Lead Sponsor
Peking University Third Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions